Antiangiogenic therapies in breast cancer

Current Opinion in Investigational Drugs

Volumn 10, Issue 12, 2009, Pages 1334-1345

  Sarmiento, Roberta ^a   D'Andrea, Mario Rosario ^a   Cacciamani, Francesca ^a   Salerno, Francesca ^a   Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Tyrosine kinase inhibitor; VEGF

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CPG 79787; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEMCITABINE; IRINOTECAN; MARIMASTAT; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; HEADACHE; HEART FAILURE; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; INTESTINE PERFORATION; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 71249123237     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med (1971) 285(21):1182-1186.
2. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer (1996) 32A(14):2534-2539.
3. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, Trent JM, Melzer PS, Hendrix MJC: Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol (1999) 155(3):739-752.
4. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi H, Yoshimoto M, Iwanaga T, Konishi F et al: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res (2001) 61(2):445-451.
5. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA (2000) 97(26):14608-14613.
6. Timar J, Tóth J: Tumor sinuses-vascular channels. Pathol Oncol Res (2000) 6(2):83-86.
7. Sood AK, Seftor EA, Fletcher MS, Gardner LG, Heidger PM, Buller RE, Seftor REB, Hendrix MJC: Molecular determinants of ovarian cancer plasticity. Am J Pathol (2001) 158(4): 1279-1288.
8. Rybak MS, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA: "Vasocrine" formation of tumor cell-lined vascular spaces: Implications for rational design of antiangiogenic therapies. Cancer Res (2003) 63(11):2812-2819.
9. Barr MP, Bouchier-Hayes DJ, Harmey JJ: Vascular endothelial growth factor is an autocrine survival factor for breast tumor cells under hypoxia. Int J Oncol (2008) 32(1):41-48.
10. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist (2000) 5(Suppl 1): 37-44.
11. Bando H: Vascular endothelial growth factor and bevacizumab in breast cancer. Breast Cancer (2007) 14(2): 163-173.
12. Guinebretière JM, Lê Monique G, Gavoille A, Bahi J, Contesso G: Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst (1994) 86(8):635-636.
13. Guidi AJ, Fischer L, Harris JR, Schnitt SJ: Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst (1994) 86(8):614-619.
14. Toi M, Matsumoto T, Bando H: Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol (2001) 2(11):667-673.
15. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD: The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009 8(9):2496-2508.
16. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H: A common 936 C/T gene polymorphysm of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (2003) 106(4):468-471.
17. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, Evangelista G, Montruccoli G, Bevilacqua G: Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol (2004) 204(2):140-146.
18. Pavlakis K, Messini I, Vrekoussis T, Yiannou P, Keramopoullos D, Louvrou N, Liakakos T, Stathopoulos EN: The assessment of angiogenesis and fibroblasts stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer (2008) 8:88.
19. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 3(5):391-400.
20. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 357(26):2666-2676.
21. Cortés-Funes H: Present and future roles of bevacizumab in breast cancer. Breast Cancer Res (2007) 9(Suppl 1):S22.
22. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 19(3):843-850.
23. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol (2001) 19(3):851-856.
24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lileubaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355 (24):2542-2550. (Pubitemid 44917502)
25. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir L et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 23(4):792-799.
26. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluoruracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 21(1):60-65.
27. Hurwitz H, Fehrenbacher W, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al: Bevacizumab plus irinotecan, fluoruracil, and leucovorin for metastatic colorectal cancer. N Eng J Med (2004) 350(23):2335-2342.
28. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG et al: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res (2006) 12(10):3124-3129. (Pubitemid 43837360)
29. Overmoyer B, Silverman P, Leeming R, Shenk R: Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat (2004) 88(Suppl 1):Abs 2088.
30. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 24(5):769-777.
31. Salter JT, Miller KD: Antiangiogenic agents in breast cancer. Cancer Invest (2007) 25(7):518-526.
32. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW: Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol (2008) 26(15S):Abs 520.
33. Russell KS, Stern DF, Polverini PJ, Bender JR: Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol (1999) 277(6 Pt 2):H2205-H2211.
34. Tortora G, Ciardiello F, Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (2008) 5(9):521-530.
35. Pegram M, Yeon C, Ku N, Gaudreault J, Slamon DJ: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat (2004) 88(Suppl 1):Abs 3039.
36. Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, Lin LS, Slamon D: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat (2006) 100(Suppl 1): Abs 301.
37. Rugo H, Dickler M, Scott J, Moore DH, Park JW: Circulating endothelial cell (CEC) and tumor cell (CTC) analysis in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC). Breast Cancer Res Treat (2004) 88(S142):Abs 3088.
38. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science (1995) 267(5205):1782-1788.
39. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 26(11): 1810-1816.
40. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, Hobday J, Rowland KM, Northfelt DW, Tenner KS, Palmieri FM, Perez EA: BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. Proc Am Soc Clin Oncol (2006) 24(18 Suppl):Abs 577.
41. Bianchi GV, Loibl S, Zamagni C, Ardizzoni A, Raab G, Siena S, Wolf C, Laferriere N, Bergamini L, Gianni L: Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. Breast Cancer Symposium, San Francisco, CA, USA (2007) 1:Abs 164.
42. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res (2005) 11(9):3369-3376.
43. Sarmiento R, Lonoce AV, Salerno F, Cacciamani F, D'Andrea MR, Torino F, Lucia M, Filippelli G, Gasparini G: Preliminary results of a dose-finding study of PTK787/ZK222584 (PTK/ ZK) in combination with weekly vinorelbine (V) and trastuzumab (T) as treatment of patients (pts) with metastatic breast cancer (MBC) overexpressing HER-2/neu, previously treated with at least one line of chemotherapy (CT). J Clin Oncol (2008) 26(15S):Abs 14672.
44. Morabito A, Carillio G, Longo R, Gasparini G: Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. Cancer J (2005) 11(3):248-251.
45. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE: Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 22(23):4683-4690.
46. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA: Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res (2004) 10(12 Part 1):4062-4067.
47. Schirner M, Hoffmann J, Menrad A, Schneider MR: Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res (1998) 4(5):1331-1336.
48. Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA (2003) 100(22):12917-12922.
49. Sarmiento R, Longo R, Gasparini G: Challenges of antiangiogenic therapy of tumors. In: Angiogenesis: An Integrative Approach from Science to Medicine. Figg WD, Folkman J (Eds), Springer Science + Business Media LLC, New York, NY, USA (2008):461-475.
50. Gasparini G, Longo R, Toi M, Ferrara N: Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat Clin Pract Oncol (2005) 2(11):562-577.
51. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 20(21):4368-4380